Update of the WHO guidance on screening for active tuberculosis

15 Jun


The World Health Organization (WHO) is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the systematic screening for tuberculosis (TB).

Coupled with other measures to scale up TB preventive treatment among populations at risk, improving adherence to treatment and introducing newer regimens for drug-resistant TB, screening for TB is one of the critical, scalable interventions available today to drive down global TB incidence as envisaged by the End TB Strategy, and towards achieving the target agreed upon by Member States at the UN High-Level Meeting on TB in 2018 to diagnose and treat at least 40 million people with active TB by the end of 2022.

WHO last updated its guidance on the systematic screening for TB in 2013. It is therefore time to review the results available since then from new studies, updated modelling and cost-effectiveness analyses, and the performance of current diagnostics and computer assisted detection of TB in chest radiography, to provide users worldwide with the best-informed guidance.

The GDG meetings will be held online in June, July and September 2020, in accordance with WHO requirements for the development of evidence-based policy guidance. The updated recommendations will be released in early 2021, as the screening module of the WHO consolidated guidelines on tuberculosis. More details of the process, inclusive of brief biographies of the experts invited to serve in the current GDG, are available here



Federal Reserve Board announces updates to Secondary Market Corporate Credit Facility (SMCCF), which will begin buying a broad and diversified portfolio of corporate bonds to support market liquidity and the availability of credit for large employers

15 Jun
Federal Reserve Board announces updates to Secondary Market Corporate Credit Facility (SMCCF), which will begin buying a broad and diversified portfolio of corporate bonds to support market liquidity and the availability of credit for large employers

WHO urges countries to enable access to fully-oral drug-resistant TB treatment regimens

15 Jun

15 June 2020 | GENEVA – The World Health Organization (WHO) is urging countries to facilitate access to fully-oral treatment regimens for patients with multidrug-resistant tuberculosis (MDR-TB) * in updated guidance released today. This will lead to major improvements in treatment outcomes and quality of life for those affected. The guidelines are accompanied by an operational handbook to facilitate rapid implementation and roll out by national TB programmes, Ministries of Health, technical partners and others involved in the treatment of patients with drug resistant TB.

“The updated guidance brings hope to the half million people struggling with MDR-TB and extensively drug-resistant TB, especially in this time of the COVID-19 pandemic,” said Dr Tereza Kasaeva, Director of WHO’s Global TB Programme.  “Patients with MDR-TB can now benefit from new shorter fully-oral treatments in the safety of their homes.”  

The consolidated guidelines on drug resistant TB treatment and the associated operational handbook recommend key updates to treatment approaches. These include:

  • New shorter fully oral regimen for patients with MDR -TB which replaces a previously recommended shorter regimen which contained an injectable agent. The newly recommended shorter regimen is 9-11 months long and research has shown that patients find it easier to complete the regimen, when compared to the longer regimens which last up to 20 months. Resistance to fluoroquinolones should be excluded prior the initiation of this regimen.
  • New shorter fully oral regimen to be used under operational research conditions for patients with MDR-TB and additional fluoroquinolone resistance. This regimen is 6-9 months long and contains a new compound that has not been used in TB regimens previously - pretomanid, in combination with bedaquiline and linezolid. Treatment outcomes for patients with MDR-TB and additional fluoroquinolone resistance have historically been low. However, with the use of this new regimen treatment outcomes may be significantly improved. The evidence gathered through the use of this regimen will also assist in further building the global evidence base on its effectiveness and safety, beyond the first study in which it was tested.  
  • Other changes outlined in the new guidelines and operational handbook include positive advice about the safety of bedaquiline use beyond six months in duration, the use of bedaquiline and delamanid together and the use of bedaquiline during pregnancy.

The above updates were signaled in December 2019 through a Rapid Communication from WHO in advance of the updated guidelines, to inform national TB programmes and other stakeholders about the key implications for treatment of MDR/RR-TB and XDR-TB to allow for rapid transition and planning at the country level.

Drug resistant TB remains a public health crisis. About half a million people fall ill with drug resistant TB annually, and about 214000 people die each year according to WHO estimates. MDR-TB is a major driver of antimicrobial resistance worldwide and threatens hard-earned gains made in the global TB response over the past two decades.  Accelerating diagnosis and treatment of MDR-TB are key components of WHO’s End TB Strategy and a key target in the political declaration of the UN High Level Meeting on TB. Yet, significant challenges remain in enabling access to diagnosis and care with only one in three affected people currently being detected globally, and just over half being treated successfully. Appropriate treatment of drug-susceptible and drug-resistant TB should be available and accessible to all who need it in line with WHO’s quest to achieve universal health coverage, and to avert deaths from a preventable, treatable and curable disease.

* MDR-TB: Resistance of Mycobacterium tuberculosis against at least isoniazid and rifampicin, the cornerstone medicines for treatment of TB. Rifampicin-resistant disease on its own requires similar clinical management as MDR-TB.



A cluster of COVID-19 in Beijing, People’s Republic of China

15 Jun

WHO is following up with Chinese authorities about a cluster of COVID-19 cases in Beijing, People’s Republic of China.

Today, officials from the National Health Commission and Beijing Health Commission briefed WHO’s China country office, to share details of preliminary investigations ongoing in Beijing.  

As of 13 June, 41 symptomatic laboratory confirmed cases and 46 laboratory confirmed cases without symptoms of COVID-19 have been identified in Beijing.

The first identified case had symptom onset on 9 June, and was confirmed on 11 June.  Several of the initial cases were identified through six fever clinics in Beijing.  Preliminary investigations revealed that some of the initial symptomatic cases had a link to the Xinfadi Market in Beijing.  Preliminary laboratory investigations of throat swabs from humans and environmental samples from Xinfadi Market identified 45 positive human samples (all without symptoms at the time of reporting) and 40 positive environmental samples.  One additional case without symptoms was identified as a close contact of a confirmed case.

All cases are in isolation and under care as needed, and contact tracing is underway.  Genetic sequencing of samples is also underway and rapid sharing of these results is important to understand the origin of the cluster and links between cases. 

WHO has offered support and technical assistance, as well as requested further information about the cluster and the investigations underway and planned.